242 related articles for article (PubMed ID: 31921693)
1. Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells.
Luo H; Wu X; Sun R; Su J; Wang Y; Dong Y; Shi B; Sun Y; Jiang H; Li Z
Front Oncol; 2019; 9():1448. PubMed ID: 31921693
[TBL] [Abstract][Full Text] [Related]
2. SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models.
Hyrenius-Wittsten A; Su Y; Park M; Garcia JM; Alavi J; Perry N; Montgomery G; Liu B; Roybal KT
Sci Transl Med; 2021 Apr; 13(591):. PubMed ID: 33910981
[TBL] [Abstract][Full Text] [Related]
3. Augmenting the Antitumor Efficacy of Natural Killer Cells via SynNotch Receptor Engineering for Targeted IL-12 Secretion.
Ahmadnia A; Mohammadi S; Yamchi A; Kalani MR; Farazmandfar T; Khosravi A; Memarian A
Curr Issues Mol Biol; 2024 Mar; 46(4):2931-2945. PubMed ID: 38666913
[TBL] [Abstract][Full Text] [Related]
4. Engineering Axl specific CAR and SynNotch receptor for cancer therapy.
Cho JH; Okuma A; Al-Rubaye D; Intisar E; Junghans RP; Wong WW
Sci Rep; 2018 Mar; 8(1):3846. PubMed ID: 29497107
[TBL] [Abstract][Full Text] [Related]
5. CAR NK92 Cells Targeting BCMA Can Effectively Kill Multiple Myeloma Cells Both In Vitro and In Vivo.
Park E; Mun HJ; Seo E; Hwang S; Lee JH; Song S; Sung H; Kim HY; Kwon MJ
Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38275419
[TBL] [Abstract][Full Text] [Related]
6. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma.
Liu Y; Di S; Shi B; Zhang H; Wang Y; Wu X; Luo H; Wang H; Li Z; Jiang H
J Immunol; 2019 Jul; 203(1):198-207. PubMed ID: 31142602
[TBL] [Abstract][Full Text] [Related]
7. A synthetic notch (synNotch) system linking intratumoral immune-cancer cell communication to a synthetic blood biomarker assay.
Fu Y; Wang T; Ronald JA
Front Pharmacol; 2023; 14():1304194. PubMed ID: 38143496
[No Abstract] [Full Text] [Related]
8. IL12 integrated into the CAR exodomain converts CD8
Hombach A; Barden M; Hannappel L; Chmielewski M; Rappl G; Sachinidis A; Abken H
Mol Ther; 2022 Feb; 30(2):593-605. PubMed ID: 34678512
[TBL] [Abstract][Full Text] [Related]
9. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma.
Choe JH; Watchmaker PB; Simic MS; Gilbert RD; Li AW; Krasnow NA; Downey KM; Yu W; Carrera DA; Celli A; Cho J; Briones JD; Duecker JM; Goretsky YE; Dannenfelser R; Cardarelli L; Troyanskaya O; Sidhu SS; Roybal KT; Okada H; Lim WA
Sci Transl Med; 2021 Apr; 13(591):. PubMed ID: 33910979
[TBL] [Abstract][Full Text] [Related]
10. Tethering IL2 to Its Receptor IL2Rβ Enhances Antitumor Activity and Expansion of Natural Killer NK92 Cells.
Jounaidi Y; Cotten JF; Miller KW; Forman SA
Cancer Res; 2017 Nov; 77(21):5938-5951. PubMed ID: 28916655
[TBL] [Abstract][Full Text] [Related]
11. Engineering a Programmed Death-Ligand 1-Targeting Monobody Via Directed Evolution for SynNotch-Gated Cell Therapy.
Zhu L; Man CW; Harrison RES; Wu Z; Limsakul P; Peng Q; Hashimoto M; Mamaril AP; Xu H; Liu L; Wang Y
ACS Nano; 2024 Mar; 18(11):8531-8545. PubMed ID: 38456901
[TBL] [Abstract][Full Text] [Related]
12. CXCL10 encoding synNotch T cells enhance anti-tumor immune responses without systemic side effect.
Xia M; Chen J; Meng G; Shen H; Dong J
Biochem Biophys Res Commun; 2021 Jan; 534():765-772. PubMed ID: 33213838
[TBL] [Abstract][Full Text] [Related]
13. IL7-IL12 Engineered Mesenchymal Stem Cells (MSCs) Improve A CAR T Cell Attack Against Colorectal Cancer Cells.
Hombach AA; Geumann U; Günther C; Hermann FG; Abken H
Cells; 2020 Apr; 9(4):. PubMed ID: 32260097
[TBL] [Abstract][Full Text] [Related]
14. [Killing effect of Robo1 targeted Chimeric Antigen Receptor modified NK92 cells against glioma and neuroblastoma cells].
Qu Y; Bi JZ
Zhonghua Yi Xue Za Zhi; 2018 Mar; 98(11):860-866. PubMed ID: 29609271
[No Abstract] [Full Text] [Related]
15. A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis.
Lu C; Guo C; Chen H; Zhang H; Zhi L; Lv T; Li M; Niu Z; Lu P; Zhu W
Mol Immunol; 2020 May; 122():200-206. PubMed ID: 32388482
[TBL] [Abstract][Full Text] [Related]
16. Novaferon gene modification promotes NK92 cell anti-tumor activity.
Zhang W; Yu B; Meng Q; Pu L; Liu B; Li F
Int Immunopharmacol; 2023 Sep; 122():110613. PubMed ID: 37421776
[TBL] [Abstract][Full Text] [Related]
17. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.
Wu X; Luo H; Shi B; Di S; Sun R; Su J; Liu Y; Li H; Jiang H; Li Z
Mol Ther; 2019 Aug; 27(8):1483-1494. PubMed ID: 31078430
[TBL] [Abstract][Full Text] [Related]
18. Comparative Evaluation of Synthetic Cytokines for Enhancing Production and Performance of NK92 Cell-Based Therapies.
Deol S; Donahue PS; Mitrut RE; Hammitt-Kess IJ; Ahn J; Zhang B; Leonard JN
GEN Biotechnol; 2023 Jun; 2(3):228-246. PubMed ID: 37363412
[TBL] [Abstract][Full Text] [Related]
19. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)].
Huang W; Liu Y; Hu Y; Gao J
Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):979-991. PubMed ID: 32567281
[TBL] [Abstract][Full Text] [Related]
20. The inducible secreting TLR5 agonist, CBLB502, enhances the anti-tumor activity of CAR133-NK92 cells in colorectal cancer.
Wang X; Qiu W; Liu H; He M; He W; Li Z; Wu Z; Xu X; Chen P
Cancer Biol Med; 2023 Sep; 20(9):662-81. PubMed ID: 37731205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]